Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2014 Feb;18(2):188-95, i-iii. doi: 10.5588/ijtld.13.0128.

Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.

Author information

1
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
2
Department of Ocular Pharmacology and Pharmacy, Dr Rajender Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
3
Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
4
Medical University, Pleven, Bulgaria.
5
Department of Ophthalmology, Dr Rajender Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
6
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
7
Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.

Abstract

OBJECTIVES:

To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH).

METHODS:

A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis treatment and were prospectively followed for the development of DIH. Plasma drug levels were measured at 0, 1, 2 and 4 h on days 1, 7 and 14 of treatment. Plasma drug levels in 15 patients who developed DIH (cases) were compared with 95 patients who did not (controls).

RESULTS:

Female sex, body mass index < 17 kg/m(2) and baseline serum albumin < 4 g/dl predicted risk of DIH on univariate analyses. Free and total plasma RMP levels (Cmax and AUC0-4) on days 1, 7 and 14 were significantly higher in cases compared to controls and predicted development of DIH. Day 7 total RMP Cmax and AUC0-4 were higher in cases (mean 26.73, standard deviation [SD] 5.72 and 47.58, SD 33.10) than in controls (7.87, SD 10.95 and 14.01, SD 10.69, respectively).

CONCLUSIONS:

Plasma RMP levels were higher in cases than in controls and independently predicted subsequent development of DIH. The Cmax of Day 7 total RMP level (cut-off 12.50 mg/l) predicted subsequent development of DIH in 93.3% of the patients.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01456845.

PMID:
24429311
DOI:
10.5588/ijtld.13.0128
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center